Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the...
Designation is based on data from the clinical development program which demonstrated clinical proof of conceptFelzartamab, an investigational anti-CD38 monoclonal antibody, is a potential...
LBL-024 Receives Breakthrough Therapy Designation in China for Extrapulmonary Neuroendocrine Carcinoma
LBL-024 for Extrapulmonary Neuroendocrine Carcinoma | Image Credit: © catalin - stock.adobe.comThe Center for Drug Evaluation of China’s National Medical Products Administration has granted...
Breakthrough Alzheimer’s Discovery: Scientists Discover New Treatment Path
New research shows astrocytes can remove Alzheimer’s-related amyloid-beta via autophagy, offering a promising new direction for treatment strategies focusing on these brain cells. An...
The CDE has Granted Breakthrough Therapy Designation to LBL-024, a Bispecific...
NANJING, China, Oct. 9, 2024 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs") announced that Center for Drug Evaluation (CDE) of National Medical...
Rising Incidence, Early Detection Challenges, and New Treatment Advances
"Ovarian cancer is becoming more and more common compared to what we used to see," begins Dr. Sankar Srinivasan, Senior Consultant in Medical Oncology...
Treatment Breakthroughs for Rare Kidney Disease
Experts share how the treatment landscape for kidney diseases like IgAN has evolved in recent years and where we’re headed.
Source link
Boehringer receives U.S. FDA Breakthrough Therapy
The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based...
Zealand Pharma announces that Boehringer receives U.S. FDA
Company announcement – No. 47 / 2024 Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and...